WR CRCN LLC

1. Moderna TX, Inc. $2,982,424 478 payments
2. Merck Sharp & Dohme Corporation $268,299 2 payments
3. Mylan Inc. $228,256 46 payments
4. Aquestive Therapeutics, Inc. $170,999 10 payments
5. Pfizer Inc. $122,707 24 payments
6. Alexion Pharmaceuticals, Inc. $98,164 18 payments
7. Ucb SA $86,892 10 payments
8. Sage Therapeutics, Inc. $70,748 2 payments
9. Sumitomo Pharma America, Inc. $48,620 8 payments
10. Biohaven Pharmaceutical Holding Company Ltd. $14,150 3 payments

1. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $2,068,637 53 payments
2. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $326,313 240 payments
3. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $319,483 35 payments
4. Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $228,256 46 payments
5. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $205,920 124 payments
6. Safety and Tolerability Study of Diazepam Buccal Soluble Film DBSF in Subjects With Epilepsy $170,999 10 payments
7. A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older $144,587 1 payment
8. A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine with a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older. $123,712 1 payment
9. A Phase 23 Randomized Doubleblind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $122,707 24 payments
10. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Sage-718 in Parkinson's Disease Cognitive Impairment $70,748 2 payments

1. Patient care $170,999 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.